专注于皮肤修复设备及自体细胞疗法的开发和商业化企业AVITA Medical（RCEL）股价暴跌27.2%。该公司在董事会决定后，已任命Cary Vance为临时首席执行官。此外该公司正在重新讨论与OrbiMed的未来契约条款，并预计2025年收入在7600万至8100万美元之间。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.